WANY
AKBA icon

Wealthspire Advisors (New York)’s Akebia Therapeutics AKBA Stock Holding History

Wealthspire Advisors (New York)’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$250K Hold
180,002
– – ﹤0.01% 785
2025
Q4 		$290K Buy
180,002
+110,002
+157% +$230K ﹤0.01% 811
2025
Q3 		$191K Buy
+70,000
New +$233K ﹤0.01% 810

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Wealthspire Advisors (New York)'s AKBA Position: Q1 2026 in Review

Wealthspire Advisors (New York) held its Akebia Therapeutics (AKBA) position steady in Q1 2026 at 180,002 shares worth $250K. The position accounts for ﹤0.01% of the portfolio, ranked #785.

Wealthspire Advisors (New York) first reported a position in AKBA in Q3 2025 and has held it in 3 quarters since. The position peaked at $290K in Q4 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Wealthspire Advisors (New York) held 180,002 shares of Akebia Therapeutics worth $250K as of Q1 2026.
  • Wealthspire Advisors (New York) left its Akebia Therapeutics share count unchanged in Q1 2026.
  • Akebia Therapeutics made up ﹤0.01% of Wealthspire Advisors (New York)'s portfolio in Q1 2026, its #785 holding.
  • Wealthspire Advisors (New York) first reported a position in Akebia Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Wealthspire Advisors (New York)'s Akebia Therapeutics position peaked at $290K in Q4 2025.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Wealthspire Advisors (New York)'s 13F filing for Q1 2026, filed 1 May 2026.